Corrona Registries: Psoriasis
Corrona launched a Psoriasis Registry, in collaboration with the National Psoriasis Foundation (NPF), in the April 2015.
The primary objective of the registry is to study comparative safety of psoriasis treatments. Secondary objectives include analyzing the epidemiology and natural history of psoriasis, comorbidities, prescribing practices, and comparative effectiveness.
The Corrona Psoriasis Registry is enrolling patients diagnosed with psoriasis who started or switched to a systemic psoriasis treatment within the previous 12 months. Data is collected from both patients and their treating dermatologists at regular outpatient office visits.
In general, clinical trials provide safety data on new treatments for 6 to 12 months, but the long-term safety profiles of agents remain unclear. As new drugs are approved for psoriasis patients, there is a growing need for an independent registry that will collect long-term real world data on safety, comorbidities, and quality of life.
- Led in conjunction with the National Psoriasis Foundation and Drs. Mark Lebwohl and Bruce Strober.
- Prospective, multicenter, observational disease-based registry.
- SAEs and AEs of special interest collected (MACE, malignancies, infection, etc).
- Data collection from both treating dermatologist and patient at routine outpatient visits.
- ~200 North American dermatology sites planned; enrollment of 10,000 psoriasis patients. First Patient in (FPI) achieved April 15, 2015.
Mark Lebwohl, MD
Sol and Clara Kest Professor and Chairman, Department of Dermatology, Icahn School of Medicine at Mount Sinai
Bruce Strober, MD, PhD
Professor, Department of Dermatology, University of Connecticut Health Center